UGUB20041, Guercio, HCRN GU18-343, Urinary Bladder Neoplasms, Cabozantinib, Atezolizumab
Research Question:
Assessing the activity of cabozantinib combined with atezolizumab in patients with
resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based
therapy or decline cisplatin-based therapy.
Basic Study Information
Purpose:
This is an open-label phase II study assessing the activity of cabozantinib combined
with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma
who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy.
Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every
3 weeks (Day 1) plus cabozantinib 40 mg orally daily (Day 1 through Day 21). Patients
will receive three cycles of treatment prior to cystectomy unless they discontinue
treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw
consent.
Location: University of Rochester Medical Center
Study Reference #: UGUB20041
Lead Researcher (Principal Investigator)
Lead Researcher:
Brendan Guercio
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search